Literature DB >> 8734771

Amitriptyline and dexamethasone combined treatment in drug-induced headache.

U Bonuccelli1, A Nuti, C Lucetti, N Pavese, G Dell'Agnello, A Muratorio.   

Abstract

Frequent or regular intake of antimigraine drugs, including analgesics, constitutes a common cause of chronic daily headache. Discontinuation of symptomatic medication can produce an increase in head pain accompanied by withdrawal symptoms. We report the favourable outcome of treating a group of outpatients with the combination of amitriptyline, dexamethasone and sumatriptan. Dexamethasone (4 mg/day) was given intramuscularly for 2 weeks, amitriptyline orally at night (50 mg/day) for at least 6 months, and sumatriptan subcutaneously to treat acute headache attacks. Eighteen out of 20 patients abstained from drug abuse. Eleven of these 18 patients showed a marked reduction in headache frequency (at least 75% in relation to the basal value), and were considered "very good responders". The other seven patients experienced at least 50% reduction in headache frequency compared to baseline. This preliminary report suggests that drug-induced headache can be treated effectively in outpatients using dexamethasone, amitriptyline and sumatriptan in combination with significant benefit in everyday life conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734771     DOI: 10.1046/j.1468-2982.1996.1603197.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

Review 1.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Drug overuse and rebound headache.

Authors:  Stephen D Silberstein; Dongmei Liu
Journal:  Curr Pain Headache Rep       Date:  2002-06

Review 3.  Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management.

Authors:  Timothy R Smith; Jill Stoneman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Migraine Headache: Immunosuppressant Therapy.

Authors:  Todd D. Rozen
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

Review 5.  When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Authors:  Domenico D'Amico; Massimo Leone; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

6.  Treatment of comorbidities of chronic daily headache.

Authors:  Sait Ashina; Richard B Lipton; Marcelo E Bigal
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

7.  Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India.

Authors:  Sanjay Prakash; Samir Saini; Kaushikkumar Ramanlal Rana; Pinaki Mahato
Journal:  J Headache Pain       Date:  2012-05-27       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.